Retatrutide vs Orforglipron — Triple Agonist Injectable vs Oral GLP-1 Compared

How Do Retatrutide and Orforglipron Compare?

Retatrutide and orforglipron are both Eli Lilly obesity drugs in Phase 3 development, but they represent fundamentally different therapeutic strategies. Retatrutide (LY3437943) is a triple agonist that activates three receptors simultaneously — GLP-1, GIP, and glucagon — and is delivered as a once-weekly subcutaneous injection. Orforglipron (LY3502970) is a non-peptide small molecule that targets the GLP-1 receptor only and is taken as a once-daily oral pill.

The two drugs are not designed to compete with each other. Lilly’s pipeline positions retatrutide as the maximum-efficacy option for patients who prioritize weight loss magnitude, while orforglipron addresses the large population of patients who prefer oral dosing or refuse injections. This complementary positioning mirrors how Lilly already markets tirzepatide (Mounjaro/Zepbound) alongside its broader pipeline. For the latest on orforglipron’s regulatory timeline, see our orforglipron FDA status tracker.

What Is the Difference in Mechanism?

Retatrutide is a triple agonist that simultaneously activates three metabolic receptors. GLP-1 receptor activation suppresses appetite and slows gastric emptying. GIP receptor activation enhances insulin sensitivity and may contribute to fat metabolism. Glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. This three-receptor approach engages metabolic pathways that single-agonist drugs do not reach.

Orforglipron is a GLP-1 receptor agonist only. It activates the same GLP-1 receptor as semaglutide and liraglutide, suppressing appetite and slowing gastric emptying. The key innovation is structural: orforglipron is a non-peptide small molecule, which allows oral delivery without the fasting requirements that constrain peptide-based oral GLP-1 drugs like the Wegovy pill. We compare it to other oral formulations in our oral obesity drugs 2026 analysis.

In short, retatrutide’s advantage is mechanistic breadth — three receptors instead of one. Orforglipron’s advantage is structural — a small molecule format that enables convenient oral dosing. For a deeper look at how the GLP-1, GIP, and glucagon pathways interact, see our triple agonist pathway explainer.

How Does the Weight Loss Data Compare?

Retatrutide reported 28.7% mean weight loss at 68 weeks in the TRIUMPH-4 Phase 3 trial (topline data, August 2025). In the earlier Phase 2 trial, the 12 mg dose achieved 24.2% weight loss at 48 weeks, published in the New England Journal of Medicine in 2023.

Orforglipron reported 12.4% mean weight loss at 72 weeks in the ATTAIN-1 Phase 3 trial (36 mg dose, August 2025). The Phase 2 trial showed up to 14.7% weight loss at 36 weeks.

Important caveat: These figures come from different clinical trials with different patient populations, baseline weights, dose titration schedules, and trial durations. Cross-trial comparisons are informative but not definitive. Only a head-to-head trial could establish true relative efficacy, and no such trial has been announced. For broader context on how both drugs compare to tirzepatide and CagriSema, see our three-way obesity drug comparison.

What Are the Side Effects of Each?

Both retatrutide and orforglipron produce gastrointestinal side effects that are characteristic of GLP-1-class drugs. The most common events in both programs are nausea, diarrhea, and vomiting. These are generally described as mild to moderate in severity and tend to decrease over time with continued dosing.

Retatrutide reported nausea in approximately 25–30% of participants in clinical trials, with diarrhea and vomiting also occurring. The triple-agonist mechanism — particularly the glucagon receptor component — raises theoretical questions about hepatic effects, though the Phase 3 safety data has not flagged liver-related signals as a primary concern.

Orforglipron reported nausea in approximately 30% of participants, with vomiting and diarrhea also dose-related. The GI side-effect profile is broadly consistent with other GLP-1 receptor agonists. Because orforglipron is a single-agonist drug, it does not carry the additional pharmacological complexity of glucagon receptor activation.

Neither drug has completed full regulatory safety review. The complete safety profiles will be defined by the totality of Phase 3 data across their respective clinical programs.

Which One Is Closer to Approval?

As of March 2026, neither retatrutide nor orforglipron is approved by the FDA or any other regulatory agency. Both reported positive Phase 3 topline data in August 2025. Neither has a publicly disclosed NDA submission date.

Retatrutide has a larger clinical program — the TRIUMPH program includes eight Phase 3 trials spanning obesity, type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), obstructive sleep apnea, HFpEF, and osteoarthritis. NDA filing is expected in late 2026 or 2027, though Eli Lilly has not confirmed a specific date.

Orforglipron is being studied in the ATTAIN program across obesity and type 2 diabetes. The NDA filing timeline has not been publicly disclosed.

It is plausible that Lilly sequences the two drugs strategically — launching them for different patient segments at different times — rather than filing both simultaneously.

Will Eli Lilly Market Both Drugs?

Almost certainly yes. Retatrutide and orforglipron serve different clinical needs within the same disease area, and Lilly has every commercial incentive to offer both.

Retatrutide — with its triple-agonist mechanism and the highest weight loss figures reported in any late-stage obesity program — positions as the premium option for patients seeking maximum efficacy. Orforglipron — as an oral GLP-1 pill without fasting restrictions — positions as the accessible option for the large population of patients who prefer pills over injections.

This is the same portfolio logic that drives Lilly’s existing strategy with tirzepatide (dual agonist, injectable, marketed as Mounjaro and Zepbound). Adding a triple-agonist injectable and an oral single-agonist creates a full spectrum: injectable dual agonist, injectable triple agonist, and oral single agonist. Each addresses a distinct segment of the obesity treatment market. Explore how all these compounds rank in our best research peptides 2026 guide.